Is Bio Techne (TECH) Fully Valued On Its Latest Earnings And Merck Linked Dividend?

Simply Wall St · 2d ago

Bio-Techne earnings event puts recent results in focus

Bio-Techne (TECH) just reported first quarter results, with sales of US$299.71 million and net income of US$28.29 million, alongside a US$0.08 quarterly dividend tied to its pending Merck KGaA transaction.

At a share price of US$72.84, Bio-Techne has logged a 22.11% year to date share price return and a 20.71% total shareholder return over the past year, suggesting momentum has been building as investors weigh the softer quarterly earnings against steady sales and the Merck KGaA linked dividend story.

See how Bio-Techne compares with other life science and healthcare names showing resilient fundamentals and potential breakouts in our curated list of solid balance sheet and fundamentals (23 results).

Bulls see Bio-Techne’s recent share price strength and steady top line as support for a richer multiple. Bears point to softer earnings and a thin dividend. Which side does the current valuation reward?

Most Popular Narrative: 3% Overvalued

On the analyst consensus Narrative on Simply Wall St, Bio-Techne screens as modestly overvalued, with a fair value estimate of about $70.73 against the recent $72.84 close. This view puts extra weight on the Merck deal and the recurring consumables story.

High consumables mix of around 81% of sales provides a largely recurring revenue base across protein science, spatial biology, diagnostics and cell therapy. This can help smooth cyclical swings in instrument demand and support more stable cash flows and earnings.

See why 9 investors see Bio-Techne as 3% overvalued.

Result: Fair Value of $70.73 (OVERVALUED)

Still, if Bio-Techne fails to re accelerate organic growth in Protein Sciences or if the Merck deal integration stumbles, the current premium could quickly look exposed.

Find out about the key risks to this Bio-Techne narrative.

Next Steps

Sentiment looks mixed, with Bio-Techne praised for some strengths yet questioned on valuation. Act while the data is fresh and review the 2 key rewards.

Looking for more Bio-Techne sized investment ideas?

If Bio-Techne has sharpened your thinking, do not stop here. Broader context from other opportunities can help you judge whether this valuation profile stacks up.